Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

The mGluR theory of fragile X mental retardation

Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580

Absence of expression of the FMR-1 gene in fragile X syndrome

Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., & Nelson, D. L. (1991) · Cell · doi:10.1016/0092-8674(91)90125-i · Cited by 1,476

Varieties of Repetitive Behavior in Autism: Comparisons to Mental Retardation

Bodfish, J. W., Symons, F. J., Parker, D. E., & Lewis, M. H. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005596502855 · Cited by 1,223

Correction of Fragile X Syndrome in Mice

Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979

DNA methylation represses FMR-1 transcription in fragile X syndrome

Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., & Warren, S. T. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.6.397 · Cited by 680

The Fragile X Syndrome Protein FMRP Associates with BC1 RNA and Regulates the Translation of Specific mRNAs at Synapses

Zalfa, F., Giorgi, M., Primerano, B., Moro, A., Di Penta, A., Reis, S., Oostra, B., & Bagni, C. (2003) · Cell · doi:10.1016/s0092-8674(03)00079-5 · Cited by 676

Advances in the Treatment of Fragile X Syndrome

Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596

Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP

Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521

Pharmacological Rescue of Synaptic Plasticity, Courtship Behavior, and Mushroom Body Defects in a Drosophila Model of Fragile X Syndrome

McBride, S. M. J., Choi, C. H., Wang, Y., Liebelt, D. A., Braunstein, E. M., Ferreiro, D., Sehgal, A., Siwicki, K. K., Dockendorff, T. C., Nguyen, H. T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.038 · Cited by 484

Individual differences in reward responding explain placebo-induced expectations and effects

Scott, D. J., Stohler, C. S., Egnatuk, C. M., Wang, H., Koeppe, R. A., & Zubieta, J.-K. (2007) · Neuron · doi:10.1016/j.neuron.2007.06.028 · Cited by 466

Regulatory and intellectual property considerations for therapeutic human stem cell‐based regenerative medicine product development: a US perspective

Mendicino, M., & Weber, D. J. (2015) · doi:10.1002/9781118846193.ch6 · Cited by 4

Association between human gray matter metabotropic glutamate receptor-5 availability in vivo and white matter properties: a [11C]ABP688 PET and diffusion tensor imaging study

Kim, S. E., Joo, Y., Son, Y., Kim, H.-K., Lee, S., Lee, M., Ido, T., & Kim, J. (2020) · Brain Structure and Function · doi:10.1007/s00429-020-02094-7 · Cited by 3

Treatments: In the waiting room

Eisenstein, M. S. (2012) · Nature · doi:10.1038/491s14a · Cited by 3

New infrastructure to support clinical translational research at the US National Institutes of Health: role of the NIH Clinical Center

Gallin, J. I. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-s2-a2 · Cited by 3

Fragile X Syndrome and Autism Spectrum Disorders

Brown, W. T., & Cohen, I. L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-391924-3.00030-2 · Cited by 3

Drug Discovery for Targeted Pharmacotherapy of Fragile X Syndrome

Scharf, S. H., Gasparini, F., Spooren, W. P. J. M., & Lindemann, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00018-4 · Cited by 3

Inverse estimation of cardiac activation times via gradient‐based optimization

Kallhovd, S., Maleckar, M. M., & Rognes, M. E. (2017) · International Journal for Numerical Methods in Biomedical Engineering · doi:10.1002/cnm.2919 · Cited by 3

Molecular mechanisms for targeted treatments in fragile X syndrome

Miranda, I., & Hagerman, R. J. (2023) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2023.21 · Cited by 3

Validation of an LC-MS/MS method for the quantitative determination of mavoglurant (AFQ056) in human plasma

Jakab, A., Winter, S., Raccuglia, M., Picard, F., Dumitras, S., Woessner, R., Mistry, S., Chudasama, J., Guttikar, S., & Kretz, O. (2012) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-6456-y · Cited by 3

Intracellular Signaling Networks in Fragile X Syndrome: Approaches to Drug Discovery and Therapeutics

Groß, C., & Bhattacharya, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00011-1 · Cited by 3

Structure, Dynamics, and Modulation of Metabotropic Glutamate Receptors

Rondard, P., Rovira, X., Goudet, C., & Pin, J. (2017) · The Receptors · doi:10.1007/978-3-319-56170-7_7 · Cited by 3

Fragile X Syndrome

Hoffmann, A., & Berry‐Kravis, E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800109-7.00020-0 · Cited by 3

Multifunctional nanoparticles—cost versus benefit of adding targeting and imaging capabilities

Sarma, A., & Das, M. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821712-2.00004-9 · Cited by 3

Elevated somatostatin interneuron long-term potentiation minimally regulates temporoammonic plasticity in a mouse model of Fragile X Syndrome

Wilson, M. A., Sumera, A., Berk, E., & Booker, S. A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1640921 · Cited by 2

Autism and Glutamate

Carlsson, M. L. (2015) · Contemporary clinical neuroscience · doi:10.1007/978-1-4939-2190-4_12 · Cited by 2

Emerging Role of Epigenetics in Human Neurodevelopmental Disorders

Mohan, K. N., & Chaillet, J. R. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-388415-2.00008-1 · Cited by 2

Therapeutic approaches for the future treatment of Fragile X

Sastre, A., Campillo, N. E., Gil, C., & Martı́nez, A. (2015) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2015.01.003 · Cited by 2

Biomimetic chimeric peptide-tethered hydrogels for human mesenchymal stem cell delivery

Shim, G., Kim, G., Choi, J., Yi, T., Cho, Y. K., Song, S. U., Byun, Y., & Oh, Y. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.09.051 · Cited by 2

A majority of parents accept newborn screening for fragile X

Levenson, D. (2011) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.34266 · Cited by 2

Reflections on Clinical Trials in Fragile X Syndrome

Jønch, A. E., & Jacquemont, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00020-2 · Cited by 2

A method to address between‐subject heterogeneity for identification of principal surrogate markers in repeated low‐dose challenge HIV vaccine studies

Spieker, A. J., & Huang, Y. (2017) · Statistics in Medicine · doi:10.1002/sim.7419 · Cited by 2

The Human Genome

Willard, H. F. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382227-7.00001-x · Cited by 4

Aptamer: Apt System for Target-Specific Drug Delivery

Goyal, M., Citu, C., Singh, N., Singla, V., & Singla, A. (2019) · Springer eBooks · doi:10.1007/978-981-13-8836-1_4 · Cited by 2

Receptor mapping using methoxy phenyl piperazine derivative: Preclinical PET imaging

Mann, G., Kadiyala, K. G., Thirumal, M., Tiwari, A. K., & Datta, A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105429 · Cited by 2

Fragile X Syndrome

Hare, E. B., Lozano, R., Partington, L. C., & Hagerman, R. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-18096-0_64 · Cited by 2

Epigenetic regulations in neurological disorders

Mondal, P., Sarkar, S., & Das, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823931-5.00010-4 · Cited by 2

Síndrome do cromossomo X frágil

Varela, A. S., Madeira, M., & Moretto, M. L. T. (2015) · Revista da SBPH · doi:10.57167/rev-sbph.18.301 · Cited by 2

Medication Management of Fragile X Syndrome

Erickson, C. A., Wink, L. K., Schaefer, T. L., & Shaffer, R. C. (2013) · Springer eBooks · doi:10.1007/978-1-4614-4788-7_188 · Cited by 2

A Framework for Evaluating Nonclinical Safety of Novel Adjuvants and Adjuvanted Preventive Vaccines

Boucher, P. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804019-5.00022-0 · Cited by 2

Critical periods and neurodevelopmental brain disorders

Meredith, R. M. (2016) · Wiley eBooks · doi:10.1002/9781118931684.ch4 · Cited by 2

The Role of Technology in Translational Science

May, L., Zatorski, C., & Vora, D. (2013) · World Medical & Health Policy · doi:10.1002/wmh3.69 · Cited by 2

Emerging Research towards the Understanding and Treatment of Autism

Wang, P. P., Hammond, R., Postma, F. R., & Healy, A. M. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00384 · Cited by 1

Epigenetic Mechanisms Shaping Spine Regulation: Unveiling the Role of Cytoskeletal Dynamics and Localized Protein Synthesis

Gupta, S., Kishore, A., Rishi, V., & Aggarwal, A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05045-7 · Cited by 1

Architecture of the Genetic Risk for Autism

Chaste, P., & Devlin, B. (2015) · Key issues in mental health (Online)/Key issues in mental health (Print) · doi:10.1159/000363590 · Cited by 1

Causal hypotheses are useful in medicine, also more limited ones – a response to R obyn B luhm on ‘capacities in psychiatry’

Hubbeling, D. A. A. (2013) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12058 · Cited by 1

Fragile X Clinical Features and Neurobiology

Leigh, M. J., & Hagerman, R. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397267-5.00044-3 · Cited by 1

Drugmakers plow more resources into autism

Sheridan, C. (2013) · Nature Biotechnology · doi:10.1038/nbt0513-367 · Cited by 1

Fragile X syndrome therapy: to respond or not to respond may be a matter of methylation

Pouladi, M. A. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01663.x · Cited by 1

mGlu5 as a potential therapeutic target for the treatment of fragile X syndrome

Robertson, L. (2013) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzt001 · Cited by 1

Fragile X Syndrome in China

Duan, R., Garber, K. B., & Jin, P. (2013) · North American Journal of Medicine and Science · doi:10.7156/najms.2013.0604181 · Cited by 1

Epigenomic and Noncoding RNA Regulation in Addictive Processes

Satterlee, J. S. (2013) · Epigenetics and human health · doi:10.1007/978-3-642-36827-1_7 · Cited by 1

Functional Assessments in Nonhuman Primate Toxicology Studies to Support Drug Development

Valentin, J., Delaunois, A. G., Lainée, P., Skinner, M. R., & Vargas, H. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417144-2.00022-6 · Cited by 1

Investigating Therapeutic Strategies for Fragile X Syndrome in Mice

Michalon, A., & Lindemann, L. (2012) · BioValley monographs · doi:10.1159/000339190 · Cited by 1

Drug Abuse Neurotoxicity: Alcohol and Nicotine as Developmental Stressors

Archer, T., Ricci, S., & Rapp‐Ricciardi, M. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_121 · Cited by 1

Phase II and III drugs for the treatment of fragile X syndrome

Politte, L. C., & McDougle, C. J. (2012) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2013.750240 · Cited by 1

Good Science for Good Pharma—A Public-Health Model

Light, D. W., & Maturo, A. F. (2015) · Palgrave Macmillan US eBooks · doi:10.1057/9781137374332_10 · Cited by 1

Translational Neuroimaging for Drug Discovery and Development in Autism Spectrum Disorders

Badura, L. L., Saxe, M., Risterucci, C., Brammer, M. J., McTighe, S. M., Ring, R. H., & Smith, D. G. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-386945-6.00009-3 · Cited by 1

Fragile X Syndrome and X-linked Intellectual Disability

Garber, K. B., Warren, S. T., & Visootsak, J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00112-9 · Cited by 1

From Molecular Pathways to ASD Therapy: Insights from Syndromic Forms of Autism

Nicholls, L. E., Ramadas, R., & Voineagu, I. (2014) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814602167_0002 · Cited by 1

Epigenetics in Autism

Ginsberg, M. R., & Natowicz, M. R. (2014) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814602167_0012 · Cited by 1

Epigenetic causes of intellectual disability—the fragile X syndrome paradigm

Tabolacci, E., & Neri, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800226-1.00006-x · Cited by 1

Targeting the GABAB Receptor in Fragile X Syndrome and Autism Spectrum Disorders

Healy, A. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-46044-4_13 · Cited by 1

Review article Epilepsy associated with autism and attention deficit hyperactivity disorder: Is there a genetic link?

Lo‐Castro, A., & Curatolo, P. (2014) · Cited by 1

Fragile X clinical features and neurobiology

Leigh, M. J., & Hagerman, R. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814409-1.00015-x · Cited by 2

Crosstalk between microRNAs and epigenetics during brain development and neurological diseases

Swaroop, S., & Adlakha, Y. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99521-4.00009-x · Cited by 1

Epigenetic causes of intellectual disability—the fragile X syndrome paradigm

Tabolacci, E., & Neri, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18516-8.00007-7 · Cited by 1

Implication of the endocannabidiome and metabolic pathways in fragile X syndrome pathophysiology

Dionne, O., Abolghasemi, A., Corbin, F., & Çaku, A. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115962 · Cited by 1

The Developmental Origins of Health and Disease: Adaptation Reconsidered

Rickard, I. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-29716-3_6 · Cited by 1

Catalytic asymmetric synthesis of Leukotriene B4

Yang, P., Zhong, J., Ji, K., Yin, J., Li, S., Wei, S., Zhou, Y., Wang, L., Wang, M., & Bian, Q. (2017) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2017.09.013 · Cited by 1

Brain in a Dish

Trujillo, C. A., Negraes, P. D., Hrvoj-Mihić, B., Lins, M. F. C., Semendeferi, K., & Muotri, A. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800105-9.00008-1 · Cited by 1

Autism Drug Trial Tracker

McCarty, N. (2022) · The Transmitter · doi:10.53053/ktuf7187 · Cited by 1

Development of Vaccines for Microbial Diseases

Trent, D. W., & Beasley, D. W. C. (2014) · doi:10.1002/9781118638033.ch11 · Cited by 1

Seeding Open Innovation Drug Discovery and Translational Collaborations to Leverage Government Funding: A Case Study of Strategic Partnership between Sanford‐Burnham and Mayo Clinic

Chung, T. D. Y., Khosla, S., Badley, A. D., & Jackson, M. R. C. (2014) · doi:10.1002/9781118778166.ch27 · Cited by 1

Ten years of bliss: the scientific ABCs of unite and conquer

Daunert, S. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-011-5530-1 · Cited by 1

Novel neurotrophic growth factor signaling pathway mediates changes in epigenetics through the redox and methylation influence of EAAT3-mediated cysteine uptake

Hodgson, N. (2012) · doi:10.17760/d20002977 · Cited by 1

Psychopharmacology

Scahill, L. D., Tillberg, C. S., & Martin, A. (2014) · Wiley eBooks · doi:10.1002/9781118911389.hautc23 · Cited by 1

Vaginal and Rectal HIV Transmission in Humanized Mice

Denton, P. W., Chateau, M., & García, J. V. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1655-9_19

Visual Spatial Learning and Memory in Fragile X Syndrome and fmr1 Knockout Mice

MacLeod, L. S. (2013) · uO Research (University of Ottawa) · doi:10.20381/ruor-6693

Diagnosis, Clinical Work Up, TNM Classification, Markers

Descotes, J., & Gauchez, A. (2012) · Springer eBooks · doi:10.1007/978-3-642-27597-5_6

Autism Spectrum Disorders: Insights from Genomics

John, J., & Hakonarso, H. (2013) · InTech eBooks · doi:10.5772/54357

The Future of Cardiac Mapping: Dawn of a New Decade

Shenasa, M., Heidary, S., Rahimian, J., & Hindricks, G. (2012) · doi:10.1002/9781118481585.ch80

Prenatal Diagnosis and the Spectrum of Involvement from Fragile X Mutations

Hagerman, R. J., Narcisa, V., & Hagerman, P. J. (2009) · doi:10.1002/9781444314342.ch9

Fragile X Syndrome: From Pathophysiology to New Therapeutic Perspectives

D’Antoni, S., Spatuzza, M., Carmela, M., Aloisi, E., Musumeci, S. A., & Vincenza, M. (2012) · InTech eBooks · doi:10.5772/31387

Genetische Diagnostik in der Sterilitätstherapie

Hehr, U., & Gassner, C. (2013) · Der Gynäkologe · doi:10.1007/s00129-013-3211-1

Involvement of mGluR5/Homer crosstalk disruption in the pathophysiology of Fragile X Syndrome

Aloisi, E. (2015) · theses.fr (ABES) · doi:10.70675/e628d840zb6adz4e63z9d1fz71559b23fe24

Chimpanzees: A Model “Model System” for Social Responsiveness

Stevens, H. E. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.02.004

Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans

Kamm, C. (2013) · Clinical Investigation · doi:10.4155/cli.13.45

Tweaking the Social Network

Gomez‐Mancilla, B. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004017

Fragile X Syndrome: Steps towards Therapy

Pop, A. (2013) · RePub (Erasmus University Rotterdam)

Adjudication of the Alleged Role of Vitamin D in the Antimicrobial Pathway

Higa, G. M., Hicks, J., & Isabella, C. (2012) · Scientifica · doi:10.6064/2012/129516

Współczesne poglądy na patogenezę idiopatycznego zespołu nerczycowego u dzieci w odniesieniu do potencjalnych nowych możliwości terapeutycznych

Grenda, R. (2016) · Pediatria Polska · doi:10.1016/j.pepo.2016.02.006

Trialing targeted therapies for autism

Murphy, D., & Ecker, C. (2012) · Nature Medicine · doi:10.1038/nm.3027

A Basic Study on Collaborative Plan of Translational Service Research for Accelerating New Drug Development

Kim, C. W., Cheol-Gyu, L., Kim, Y. S., & Yoo, W. (2014) · Journal of Korea Service Management Society · doi:10.15706/jksms.2014.15.1.014

Recent disclosures of clinical candidates - Highlights from the Society for Medicines Research Symposium, held on December 8, 2011 at The National Heart and Lung Institute, South Kensington, London, UK

ALDERTON, W. K., Collingwood, S. P., & Ratcliffe, A. J. (2012) · Drugs of the Future · doi:10.1358/dof.2012.037.03.1782930

What Mechanisms Induce Methylation of FMR1 Gene Full Mutation? A Still Unanswered Question

Tabolacci, E., & Neri, G. (2016) · Epigenetics and human health · doi:10.1007/978-3-319-27186-6_8

Outcome Measures in Clinical Trials for Fragile X Syndrome: The Search for Sensitive Neurocognitive Assays

Guy, J., & Scerif, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00021-4

Seizing Opportunities for Markets of Discovery: The Reconfigurations of Value Chains in Pharmaceutical Industry in the Global South

de Pádua, M. H., Fontes, M., & Sousa, C. (2018) · Science Technology and Society · doi:10.1177/0971721818762930

Liquid Metal Printed Biosensor

Liu, J., & Yi, L. (2018) · Springer series in biomaterials science and engineering · doi:10.1007/978-981-10-5607-9_13

The design of a global HIV vaccine

Kim, J. H., & Michael, N. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0695-2.00008-0

Losartan

Hubbert, K., & Clement, R. D. (2021) · JBJS Journal of Orthopaedics for Physician Assistants · doi:10.2106/jbjs.jopa.20.00030

Disability Rights: Positive Peace Through a Disability Lens

Watene, R. F. (2021) · Springer eBooks · doi:10.1007/978-981-15-3877-3_26-1

Fragile X clinical features and neurobiology

Leigh, M. J., & Hagerman, R. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00022-2

Considering Medications for Behavior and Mental Health Problems

Volkmar, F. R., & Wiesner, L. (2017) · doi:10.1002/9781119426981.ch11

Genetic defects behind fragile X‐related disorders more common

(2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.35948

Cytogenetics

Bacino, C. A., & Lee, B. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0755-7.00076-2

Prenatal Diagnosis and the Spectrum of Involvement from Fragile X Mutations

Hagerman, R. J., & Hagerman, P. J. (2015) · doi:10.1002/9781118981559.ch7

Maternal FMR1 alleles expansion in newborns during transmission: a prospective cohort study

Shahid, R. K., Yasin, M., Rehman, Z. U., Jadoon, H. N., Tahir, H., Meraj, N., Khan, N. A., Zubair, M., Zulfiqar, I., Nowshid, M., et al. (2022) · Pediatric Research · doi:10.1038/s41390-022-02128-2

considering medications for behavior and mental health problems

(2021) · doi:10.1002/9781394259007.ch13

Fragile X clinical features and neurobiology

Leigh, M. J., & Hagerman, R. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00036-4

Dysregulation of an H3K79me2-dependent epigenetic barrier impairs neural progenitor cell proliferation and differentiation in Fragile X syndromePreprint

Dionne, O., Gaudreau, G.-L., Bergis, C., Avino, M., Sabatié, S., Corbin, F., & Laurent, B. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.31.673358

Epigenetic modification of the FMR1 gene in fragile X patients leads to a differential response to the mGluR5 antagonist AFQ056

Jacquemont, S., Curie, A., Portes, V. D., Torrioli, M. G., Berry‐Kravis, E., Hageman, R., Ramos, F. J., Cornish, K. M., He, Y., & neri, G. (2011) · Cited by 2

The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro

Tabolacci, E., Pirozzi, F., Gomez‐Mancilla, B., Gasparini, F., & Neri, G. (2012) · BMC Medical Genetics · doi:10.1186/1471-2350-13-13 · Cited by 15

Progress toward therapeutic potential for AFQ056 in Fragile X syndrome

Doering, L. C., Sourial, M. M., & Cheng, C. (2013) · Journal of Experimental Pharmacology · doi:10.2147/jep.s27044 · Cited by 8

mGlu5 as a potential therapeutic target for the treatment of fragile X syndrome

Robertson, L. (2013) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzt001 · Cited by 1

Fragile X syndrome therapy: to respond or not to respond may be a matter of methylation

Pouladi, M. A. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01663.x · Cited by 1